TENX Tenax Therapeutics

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast.

Format: Fireside Chat

Presenter: Chris Giordano, President & Chief Executive Officer

Date and time: November 13, 2024 at 1:00 PM EST

Webcast:

The live and archived webcast of the presentation will be accessible from the Company’s investor relations .

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize I.V., subcutaneous, and oral formulations of levosimendan. Tenax also is developing a unique oral formulation of imatinib. For more information, visit Tenax’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contacts

Investor Contact:

John Fraunces

Managing Director

LifeSci Advisors, LLC

C: 917-355-2395, or

Brian Mullen

LifeSci Advisors, LLC

C: 203-461-1175



EN
31/10/2024

Underlying

TENXTenax Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tenax Therapeutics

 PRESS RELEASE
Free
TENX Tenax Therapeut...

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Pr...

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results f...

May 14, 2025 1 EN
 PRESS RELEASE
Free
TENX Tenax Therapeut...

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual H...

Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. Details of presentation: Format: Corporate Presentation Participants: Chris Giordano, P...

March 31, 2025 1 EN
 PRESS RELEASE
Free
TENX Tenax Therapeut...

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...

Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 Phase 3 LEVEL Study Expansion Increases Statistical Power; Enrollment Completion Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., March 25, 2025 (GLOBE NEWSWIRE) --...

March 25, 2025 1 EN
 PRESS RELEASE
Free
TENX Tenax Therapeut...

Tenax Therapeutics Announces $25 Million Private Placement

Tenax Therapeutics Announces $25 Million Private Placement CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private...

March 5, 2025 1 EN
 PRESS RELEASE
Free
TENX Tenax Therapeut...

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-10...

Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 Agreement by FDA to Initiate Second Global Phase 3 Study, LEVEL-2, with First Patient Expected to be Enrolled this Year CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical compan...

March 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch